Skip to main content

Mineralys Therapeutics, Inc. (MLYS) research

Mineralys Therapeutics, Inc.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$28.02
As of

Mineralys Therapeutics, Inc. (MLYS): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.

As of . Source: SEC EDGAR filings for MLYS. Method and limitations.

SHARE THIS CARD

Share the MLYS intelligence card

A branded snapshot of MLYS: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion MLYS intelligence card preview
Post to X
LIVE TERMINAL

See MLYS live in the terminal

Track MLYS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live MLYS terminal, free

Active signals for MLYS

FREE, NO ACCOUNT

Every signal on MLYS, as it fires

You are seeing 5 of 24 signals recorded on MLYS since 2026-05-26.

The five above all landed on 2026-09-06. The other 19 were recorded on 4 other days. 20 of the 24 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in MLYS (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 603170101 · 2026Q2$33M0.01%,
CITADEL ADVISORS LLCCUSIP 603170101 · 2026Q2$12.6M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 603170101 · 2026Q2$10.2M0.01%,
D. E. Shaw & Co., Inc.CUSIP 603170101 · 2026Q2$9.5M0.00%,
TWO SIGMA INVESTMENTS, LPCUSIP 603170101 · 2026Q2$4.4M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MLYS

MLYS against its peers

MLYS's return on equity of -23.9% ranks in the 82nd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.

MetricMLYSPeer medianPercentilen
Revenue FYn/a70.8Mn/a13
Operating marginn/a-512.9%n/a13
Net marginn/a-483.6%n/a13
Return on equity-23.9%-48.3%8218

Peers (19): IRON, NRIX, NAMS, VRDN, PGEN, PHVS, VERA, IMNM, BEAM, ATAI, ZLAB, SLS, ARQT, MBX, QURE, BCRX, PVLA, SRPT, CLDX. Left out: BRVE (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (MLYS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more MLYS signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MLYSand get the insider, 13F, options, and confluence read in one view.

Open the live MLYS terminal, free